The global peritoneal dialysis (PD) market is undergoing rapid transformation, emerging as a pivotal segment in the renal care industry. Valued at US$ 6.1 billion in 2025, the market is projected to reach US$ 11.6 billion by 2032, expanding at a CAGR of 9.7% during the forecast period. According to Persistence Market Research, this growth is driven by a surge in End-Stage Renal Disease (ESRD) cases, increasing demand for home-based treatments, and favorable reimbursement reforms in major economies.
Continuous Ambulatory Peritoneal Dialysis (CAPD) remains the leading dialysis type due to its cost-effectiveness, simplicity, and suitability for resource-limited settings. Meanwhile, Asia Pacific stands out as the dominant regional market, accounting for approximately 39.2% of global share in 2025. This is fueled by high ESRD prevalence, limited hemodialysis infrastructure, and expanding government-backed home dialysis initiatives, particularly in China and India.
Key Highlights from the Report:
➤ The global peritoneal dialysis market is set to grow at a 9.7% CAGR from 2025 to 2032.
➤ PD fluids will hold around 54.3% of the market share in 2025 due to recurring demand and innovation in biocompatible solutions.
➤ CAPD accounts for over 65% share in 2025, favored in low-resource settings without stable electricity.
➤ Asia Pacific leads the market in 2025, supported by public health programs and local manufacturing.
➤ Remote monitoring integration is revolutionizing PD with enhanced clinical oversight.
➤ Policy incentives in the U.S. are accelerating home dialysis adoption rates.
𝐆𝐞𝐭 𝐚 𝐒𝐚𝐦𝐩𝐥𝐞 𝐂𝐨𝐩𝐲 𝐨𝐟 𝐑𝐞𝐬𝐞𝐚𝐫𝐜𝐡 𝐑𝐞𝐩𝐨𝐫𝐭 (𝐔𝐬𝐞 𝐂𝐨𝐫𝐩𝐨𝐫𝐚𝐭𝐞 𝐌𝐚𝐢𝐥 𝐢𝐝 𝐟𝐨𝐫 𝐐𝐮𝐢𝐜𝐤 𝐑𝐞𝐬𝐩𝐨𝐧𝐬𝐞): https://www.persistencemarketresearch.com/samples/35550
Market Segmentation:
Segmentation by Dialysis Type:
The market is primarily divided into Continuous Ambulatory Peritoneal Dialysis (CAPD) and Automated Peritoneal Dialysis (APD). CAPD leads with 65.2% share in 2025, offering affordability and independence from electricity, making it ideal for rural and underserved populations. APD, performed overnight using cyclers, is gaining traction in developed economies due to lifestyle convenience, improved fluid management, and compatibility with telehealth.
Segmentation by Product Type:
Product categories include cyclers, fluids, and accessories. Fluids dominate with a projected 54.3% market share in 2025, driven by recurring usage and advancements in neutral pH, low-glucose formulations. Cyclers, essential for APD, are increasingly equipped with connectivity features enabling remote monitoring. Accessories such as catheters and transfer sets complement the ecosystem, providing consistent ancillary revenue streams for manufacturers.
Regional Insights:
Asia Pacific:
Asia Pacific is the largest regional market in 2025, led by China, India, and Japan. Government-backed programs, expanded reimbursement, and domestic manufacturing of PD consumables are reducing costs and improving access. India’s public hospitals are gradually integrating PD under the Pradhan Mantri National Dialysis Program, enhancing penetration in semi-urban and rural areas.
North America:
The U.S. dominates the North American PD market through strong policy incentives such as the ESRD Treatment Choices (ETC) model. Providers like DaVita and Fresenius are leveraging telehealth platforms and connected cyclers to expand home dialysis adoption. Canada maintains steady utilization rates but faces plateauing growth due to patient aging and in-center treatment preference.
Market Drivers:
Rising ESRD Prevalence – Increasing rates of diabetes, hypertension, and aging populations are fueling ESRD incidence worldwide.
Shift to Home-Based Care – Decentralization of dialysis services reduces hospital strain and supports patient convenience.
Technological Advancements – Integration of remote monitoring systems and digitally enabled cyclers is improving patient outcomes.
Market Restraints:
Elderly Reluctance to Use Cyclers – Older patients in developed economies often opt for in-center hemodialysis due to technophobia and physical limitations.
Infrastructure Gaps – In low-income regions, lack of trained PD nurses and supply chain challenges can hinder adoption.
Cultural Preferences – In certain markets like Germany, entrenched in-center dialysis culture slows PD uptake.
Market Opportunities:
Preventive CKD Management – Early integration of PD in CKD pathways can significantly improve uptake before ESRD onset.
Local Manufacturing Expansion – Cost-effective domestic production in Asia Pacific is lowering treatment costs and boosting accessibility.
Wearable Dialysis Devices – Emerging innovations in portable and wearable PD systems could open new patient segments globally.
Reasons to Buy the Report:-
✔ Gain comprehensive insights into market growth drivers, restraints, and opportunities through 2032.
✔ Understand regional market trends, competitive strategies, and emerging healthcare policies.
✔ Identify the fastest-growing segments for investment prioritization.
✔ Access in-depth analysis of product innovation and technology adoption trends.
✔ Leverage competitive intelligence to benchmark against leading players.
Company Insights:
✦ Baxter International Inc.
✦ Fresenius Kabi AG
✦ Medtronic plc
✦ Utah Medical Products, Inc.
✦ Glomeria Therapeutics
✦ Poly Medicure Ltd.
✦ Cook Medical Inc.
✦ CardioMed Supplies, Inc.
✦ Medical Components, Inc.
✦ Others
Recent Developments:
June 2025: Vantive committed over US$ 1 billion to R&D and production expansion, focusing on digitally enabled PD therapies.
October 2024: Baxter International restored full supply of PD solutions to pre-Hurricane Helene levels, prioritizing pediatric care facilities.
Conclusion:
The peritoneal dialysis market is on a strong growth trajectory, propelled by the dual forces of rising ESRD prevalence and the global healthcare shift toward home-based treatment models. With projected revenues climbing from US$ 6.1 billion in 2025 to US$ 11.6 billion by 2032, and a CAGR of 9.7%, the sector presents robust opportunities for innovation, policy support, and investment.
Advancements in PD fluids, cycler connectivity, and remote monitoring are redefining treatment accessibility and patient experience. While adoption barriers—such as elderly patient reluctance and infrastructure limitations—remain, targeted education programs, assisted PD models, and preventive CKD integration are addressing these challenges.
Read Related Reports:
